title: Use of Ozone-Depleting Substances. Direct final rule.
abstract: The Food and Drug Administration (FDA, the Agency, or we) is amending its regulation on uses of ozone-depleting substances (ODSs), including chlorofluorocarbons (CFCs), to remove the designation for certain products as "essential uses" under the Clean Air Act. Essential-use products are exempt from the ban by FDA on the use of CFCs and other ODS propellants in FDA-regulated products and from the ban by the Environmental Protection Agency (EPA) on the use of ODSs in pressurized dispensers. The products that will no longer constitute an essential use are: Sterile aerosol talc administered intrapleurally by 
  thoracoscopy for human use and metered-dose atropine sulfate aerosol human drugs administered by oral inhalation. FDA is taking this action because alternative products that do not use ODSs are now available and because these products are no longer being marketed in versions that contain ODSs.
mesh_terms: D000335:Aerosol Propellants / Q000009:adverse effects* / Q000627:therapeutic use; D000393:Air Pollutants / Q000009:adverse effects*; D001285:Atropine / Q000627:therapeutic use; D017402:Chlorofluorocarbons / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D062966:Ozone Depletion / Q000331:legislation & jurisprudence* / Q000517:prevention & control; D013627:Talc / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D000335:Aerosol Propellants; D000393:Air Pollutants; D017402:Chlorofluorocarbons; D013627:Talc; D001285:Atropine